Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Inotuzumab and blinatumomab: the most exciting ALL news from EHA 2017

David Marks • 24 Jun 2017
EHA 2017
Acute Lymphoblastic Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

David Marks, MD, PhD from University Hospitals Bristol NHS Foundation Trust, Bristol, UK, describes his acute lymphoblastic leukemia (ALL) highlights from the European Society of Hematology congress in Madrid, Spain. He discusses two positive randomised trials demonstrating the effect of inotuzumab and blinatumomab in relapsed/refractory ALL patients. He also talks about CAR-T cells and the fact that there are some concerns about the effects these agents will have on patients.

More from David Marks

The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
The importance of MRD assessment before alloSCT in ALL
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023

Related Videos

Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
10:54
Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
Samer Srour • 19 Sep 2026
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
1:20
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera • 14 Sep 2026
NGS-MRD assessment and targeted treatment selection in ALL
1:48
NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera • 14 Sep 2026
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
3:52
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
Bijal Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals